AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16546771 — intervention group
Group type: COMPARATOR
Intervention: Control group (home respiratory exercise program)
Number of subjects: 62
Study 12788859 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (5-15 microg/kg x d s.c.)
Number of subjects: 18
Study 12788859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10819321 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fall-related self-efficacy (FES score < or = 75)
Number of subjects: 528
Study 10819321 — intervention group
Group type: COMPARATOR
Intervention: High fall-related self-efficacy (FES score = 100)
Number of subjects: 528
Study 10819321 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor fall-related self-efficacy
Number of subjects: 528
Study 10819321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfallers afraid of falling
Number of subjects: 528
Study 8838483 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol (EE)
Number of subjects: 40
Study 8838483 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol (EE)
Number of subjects: 40
Study 8838483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (20 micrograms EE and 30 micrograms EE)
Number of subjects: 40
Study 1336735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 8
Study 1336735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3938681 — intervention group
Group type: EXPERIMENTAL
Intervention: Transderm‐Nitro (TDN)
Number of subjects: 65
Study 3938681 — intervention group
Group type: COMPARATOR
Intervention: Nitro‐Dur (ND)
Number of subjects: 65
Study 29983189 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ointment dressings
Number of subjects: 96
Study 29983189 — intervention group
Group type: COMPARATOR
Intervention: Mepitel Ag®
Number of subjects: 96
Study 30149076 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Physical Activity and Sleep Health intervention
Number of subjects: 275
Study 30149076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Health-Only intervention
Number of subjects: 275
Study 30149076 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control group
Number of subjects: 275
Study 26685010 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate with prednisone
Number of subjects: 762
Study 25332325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-genistein (LG) supplement (100 mg isoflavones/d)
Number of subjects: 57
Study 25332325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-genistein (HG) supplement (100 mg isoflavones/d)
Number of subjects: 57
Study 25332325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplements
Number of subjects: 57
Study 25332325 — intervention group
Group type: COMPARATOR
Intervention: Isoflavone supplementation
Number of subjects: 57
Study 22378566 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 405
Study 22378566 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 405
Study 22378566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 22378566 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (combined 50 mg and 100 mg)
Number of subjects: 405
Study 22378566 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 405
Study 20551021 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (Group F)
Number of subjects: 40
Study 20551021 — intervention group
Group type: COMPARATOR
Intervention: Periarticular infiltration of local anaesthetic (Group I)
Number of subjects: 40
Study 18635219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation
Number of subjects: 856
Study 18635219 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation
Number of subjects: 856
Study 16207627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 179
Study 16207627 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 179
Study 11792874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered educational package
Number of subjects: 222
Study 11792874 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple advice regarding NSAID use)
Number of subjects: 222
Study 10412878 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg daily for 16 weeks)
Number of subjects: 50
Study 10412878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg daily for 16 weeks)
Number of subjects: 50
Study 10412878 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly men (cross-sectional study)
Number of subjects: 50
Study 7600840 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 10
Study 7600840 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (low-dose vs. high-dose)
Number of subjects: 10
Study 7600840 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids in patients with Gram-negative infection
Number of subjects: 10
Study 2393268 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cefpodoxime proxetil (single dose)
Number of subjects: 16
Study 2393268 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cefpodoxime proxetil (steady state, after 5 days)
Number of subjects: 16
Study 2393268 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cefpodoxime proxetil (single dose)
Number of subjects: 16
Study 2393268 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cefpodoxime proxetil (steady state, after 5 days)
Number of subjects: 16
Study 2393268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing regimens (200 mg and 400 mg)
Number of subjects: 16
Study 7290471 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (420 mg/die/os)
Number of subjects: 55
Study 7290471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30952509 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 590
Study 30952509 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 590
Study 30952509 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + Multivitamins
Number of subjects: 590
Study 30952509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study 28440888 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive dual-task training (gait and cognitive tasks trained separately)
Number of subjects: 121
Study 28440888 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated dual-task training (gait and cognitive tasks trained simultaneously)
Number of subjects: 121
Study 28440888 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 121
Study 25950503 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorouracil cream, 5% (n=468)
Number of subjects: 932
Study 25950503 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream (n=464)
Number of subjects: 932
Study 24053647 — intervention group
Group type: EXPERIMENTAL
Intervention: HTK cardioplegia
Number of subjects: 60
Study 24053647 — intervention group
Group type: COMPARATOR
Intervention: WBC
Number of subjects: 60
Study 24053647 — intervention group
Group type: EXPERIMENTAL
Intervention: HTK with topical cooling
Number of subjects: 60
Study 24053647 — intervention group
Group type: COMPARATOR
Intervention: HTK without topical cooling
Number of subjects: 60
Study 21355946 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga practice (90 min twice weekly for 8 weeks)
Number of subjects: 18
Study 21355946 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed, noninterventional control group (n = 9)
Number of subjects: 18
Study 19787222 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor-beta (ER-beta) expression
Number of subjects: 80
Study 19787222 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-beta expression
Number of subjects: 80
Study 17096171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular 100 mg of tramadol in 20 ml normal saline and periarticular incisional injection of 10 ml bupivacaine 0.5% (Group TB)
Number of subjects: 74
Study 17096171 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular 20 ml 0.25% and periarticular incisional 10 ml 0.5% bupivacaine injections (Group BB)
Number of subjects: 74
Study 12439083 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (C)
Number of subjects: 98
Study 12439083 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 98
Study 10726235 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (mean once‐daily dose 111.5 +/- 36.3 mg)
Number of subjects: 18
Study 10726235 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate (mean once‐daily dose 17.5 +/- 7.5 mg)
Number of subjects: 18
Study 8746642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium, high potassium, high magnesium salt (mineral salt)
Number of subjects: 89
Study 8746642 — intervention group
Group type: COMPARATOR
Intervention: Common salt (control)
Number of subjects: 89
Study 2029287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally administered diazepam (R‐DZP)
Number of subjects: 41
Study 2029287 — intervention group
Group type: COMPARATOR
Intervention: Non-users of R‐DZP
Number of subjects: 41
Study 6459190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tice lyophilized BCG
Number of subjects: 130
Study 6459190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteur lyophilized BCG
Number of subjects: 130
Study 6459190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteur fresh-frozen BCG
Number of subjects: 130
Study 6459190 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 130
Study 6459190 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatments (all types)
Number of subjects: 130
Study 29800372 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) after Abaloparatide (ABL)
Number of subjects: 1139
Study 29800372 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (ALN) after Placebo (PBO)
Number of subjects: 1139
Study 28756050 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 60
Study 28756050 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal switch
Number of subjects: 60
Study 28756050 — intervention group
Group type: COMPARATOR
Intervention: Comparison between gastric bypass and duodenal switch
Number of subjects: 60
Study 26262904 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting oral methylphenidate, taken two or three times daily; each dose ranged between 0.3 and 1.0 mg/kg.
Number of subjects: 154
Study 23218404 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryophyllum pinnatum (BP) 350 mg/day (3×2 capsules)
Number of subjects: 20
Study 23218404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 20
Study 23218404 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 22003163 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 137
Study 22003163 — intervention group
Group type: EXPERIMENTAL
Intervention: Late‐Life Function and Disability Instrument (LLFDI)
Number of subjects: 137
Study 18427025 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 257
Study 18427025 — intervention group
Group type: COMPARATOR
Intervention: Small-incision cholecystectomy
Number of subjects: 257
Study 16555023 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic India ink tattooing (n = 21; tattooed group, TG)
Number of subjects: 47
Study 16555023 — intervention group
Group type: COMPARATOR
Intervention: Conventional localization methods (n = 26; non‐tattooed group, NTG)
Number of subjects: 47
Study 12510801 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide treatment for a median of 19 months
Number of subjects: 0
Study 12510801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with calcium and vitamin D)
Number of subjects: 0
Study 11072392 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-skills Relapse Prevention (RP) treatment
Number of subjects: 160
Study 11072392 — intervention group
Group type: COMPARATOR
Intervention: Health Belief Model (HBM) treatment
Number of subjects: 160
Study 7576392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrices (1100 ppm F-)
Number of subjects: 0
Study 7576392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrices (2800 ppm F-)
Number of subjects: 0
Study 7576392 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 7576392 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyampholyte-NaF delivery system (1100 ppm F-)
Number of subjects: 0
Study 7576392 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including fluoride dentifrices)
Number of subjects: 0
Study 2254698 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized software exercise electrocardiographic program
Number of subjects: 20
Study 2254698 — intervention group
Group type: COMPARATOR
Intervention: Two experienced cardiologists without computerized measurements
Number of subjects: 20
Study 2254698 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized measurements
Number of subjects: 20
Study 2254698 — intervention group
Group type: COMPARATOR
Intervention: Non-computerized measurements
Number of subjects: 20
Study 6776974 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (2 litre min-1 oxygen and 13 litre min-1 air) for 30 min followed by low-flow oxygen therapy (2 litre min-1 dry oxygen) for 30 min
Number of subjects: 13
Study 6776974 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen therapy (2 litre min-1 dry oxygen) for 30 min followed by high-flow oxygen therapy (2 litre min-1 oxygen and 13 litre min-1 air) for 30 min
Number of subjects: 13
Study 30905130 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive 1,000 mg/day of mangosteen pericarp
Number of subjects: 150
Study 30905130 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 150
Study 30030720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir plus ribavirin for 24 weeks
Number of subjects: 117
Study 30030720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir plus ribavirin for 12 weeks
Number of subjects: 117
Study 30030720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir plus ribavirin for 12 weeks in patients with NS5A RASs
Number of subjects: 117
Study 26762282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sailuotong (SLT)
Number of subjects: 16
Study 26762282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24452498 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudinal discussion
Number of subjects: 167
Study 24452498 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative talk
Number of subjects: 167
Study 24452498 — intervention group
Group type: EXPERIMENTAL
Intervention: Role play
Number of subjects: 167
Study 24452498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear induction
Number of subjects: 167
Study 24452498 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative website
Number of subjects: 167
Study 24452498 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 167
Study 22196196 — intervention group
Group type: EXPERIMENTAL
Intervention: Light extrusive forces (25 g)
Number of subjects: 10
Study 22196196 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy extrusive forces (225 g)
Number of subjects: 10
Study 21058477 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetration needling combined with electroacupuncture on the back shu points and Governor Vessel points for 30 days
Number of subjects: 60
Study 21058477 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen capsules for 30 days
Number of subjects: 60
Study 18186237 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators
Number of subjects: 400
Study 18186237 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD diagnosis
Number of subjects: 400
Study 18186237 — intervention group
Group type: COMPARATOR
Intervention: Current smoking status
Number of subjects: 400
Study 15774170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control of blood glucose by intensive insulin therapy (maintenance of blood glucose at a level between 4.4 and 6.1 mmol/L)
Number of subjects: 54
Study 15774170 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control of blood glucose by intensive insulin therapy
Number of subjects: 54
Study 15774170 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (maintenance of glucose at a level between 10.0 and 11.1 mmol/L)
Number of subjects: 54
Study 11821798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with chemotherapy and radiotherapy
Number of subjects: 0
Study 11821798 — intervention group
Group type: COMPARATOR
Intervention: Intra- or postoperative hyperthermia treatment
Number of subjects: 0
Study 11821798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia for unresectable or local recurrent rectal cancer
Number of subjects: 0
Study 10221191 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon anesthesia
Number of subjects: 25
Study 10221191 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 25
Study 7602364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for intermediate-grade lymphomas
Number of subjects: 44
Study 7602364 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy or therapy for low-grade lymphoma or Hodgkin's disease
Number of subjects: 44
Study 7602364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for intermediate-grade lymphoma
Number of subjects: 44
Study 7602364 — intervention group
Group type: COMPARATOR
Intervention: Other therapies (including salvage therapies)
Number of subjects: 44
Study 7602364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy directed at large-cell lymphomas
Number of subjects: 44
Study 30870102 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of Behavioural Activation followed by 8 weeks of daily SMS messages (INT)
Number of subjects: 59
Study 30870102 — intervention group
Group type: COMPARATOR
Intervention: Single (attention control) session focused on the importance of motivation followed by 8 weeks of motivational SMS messages (MOT)
Number of subjects: 59
Study 30234568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean storage age of blood transfusions (25.6 +/- 10.2 days)
Number of subjects: 303
Study 30234568 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of very old blood (mean of 5.3 +/- 10.7 units)
Number of subjects: 303
Study 30234568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean storage age of blood transfusions
Number of subjects: 303
Study 30234568 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of very old blood
Number of subjects: 303
Study 30234568 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusions (6,786 total)
Number of subjects: 303
Study 28766403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes HealthSense website usage after group education session
Number of subjects: 311
Study 28766403 — intervention group
Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 311
Study 28766403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes HealthSense website usage
Number of subjects: 311
Study 26275599 — intervention group
Group type: EXPERIMENTAL
Intervention: GentleWave System (GWS) treatment
Number of subjects: 45
Study 26275599 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary instrumentation and needle irrigation
Number of subjects: 45
Study 26275599 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 45
Study 22729012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (1.5 g mixed in 100 cc of saline)
Number of subjects: 150
Study 22729012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular tranexamic acid (1.5 g mixed in 100 cc of saline)
Number of subjects: 150
Study 22729012 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline administered into the knee joint cavity and intravenously)
Number of subjects: 150
Study 21613336 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 75
Study 21613336 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 75
Study 19961341 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 106
Study 19961341 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 106
Study 16005883 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 115
Study 16005883 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 115
Study 16005883 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Simvastatin
Number of subjects: 115
Study 15224471 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy in patients with NMNG and thyroid carcinoma
Number of subjects: 80
Study 11725155 — intervention group
Group type: COMPARATOR
Intervention: HRT 1 (1 mg of 17beta‐oestradiol per day continuously plus 0.025 mg gestodene on days 17‐28 of each 4‐week cycle)
Number of subjects: 226
Study 11725155 — intervention group
Group type: COMPARATOR
Intervention: HRT 2 (1 mg of 17beta‐oestradiol per day continuously plus gestodene in each third cycle only)
Number of subjects: 226
Study 11725155 — intervention group
Group type: EXPERIMENTAL
Intervention: No HRT
Number of subjects: 226
Study 9165186 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg fluoride daily in the form of a tablet
Number of subjects: 798
Study 9165186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study 7896628 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 degrees C and 20% relative humidity (T40)
Number of subjects: 12
Study 3309479 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (one-dose protocol): All protamine infused within 10 minutes after termination of cardiopulmonary bypass.
Number of subjects: 20